Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine plus low-dose cytarabine for higher-risk myelodysplastic syndrome after hypomethylating agent failure
ChiCTR1900026266Phase 4Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine and cytarabine in myelodysplastic syndrome (MDS), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Overall survival. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
cladribinecytarabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR1900026266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026266.